3 ETFs That Historically Perform Well in the Final Weeks of May

The article highlights seasonal strength in May for the Nasdaq-100, with the Invesco NASDAQ 100 ETF (QQQM) tracking an index that has averaged a 1.6% gain in May over the past two decades. It also points to defensive exposure via the State Street Consumer Staples ETF, which is up 10.5% year to date and historically performs well from late April through Thanksgiving, and to the Vanguard Health Care ETF as a low-AI-trade-correlated, seasonally favorable option. The piece is mostly tactical and educational, with limited immediate price impact.

Analysis

The setup is less about “May seasonality” and more about factor rotation from crowded duration-sensitive growth into cash-flow durability. That matters because the article’s three preferred sleeves are not just defensive; they are effectively low-beta, high-quality factor expressions with different catalysts: QQQM for momentum persistence, XLP for earnings visibility, and VHT for secular growth with lower AI overlap. In a tape where incremental capital is still chasing the AI complex, the second-order opportunity is to own the beneficiaries of deconcentration rather than simply hiding in cash.

The more interesting signal is relative rather than absolute performance. If tech weakens into June while staples and healthcare stay bid, breadth should deteriorate even if indices hold up, which typically compresses dispersion and favors pair trades over outright beta. Consumer staples’ outperformance can continue longer than investors expect because falling realized volatility tends to support crowded defensive rotation after a strong earnings season, while healthcare often benefits from delayed re-risking by PMs who missed the first leg in AI and need an uncrowded place to add equity exposure.

The main risk is that the market is still in a “buy the dip in mega-cap growth” regime, so any mild pullback may be short-lived and punish premature defense. For QQQM specifically, the opportunity is tactical: June weakness has historically been the cleaner entry point than late May, so chasing today may compress reward-to-risk. For VHT, the stronger thesis is not seasonality alone but the combination of low correlation to AI and a longer runway for pharma leadership; if rotation broadens, healthcare can become a late-cycle relative winner rather than just a safe haven.

Key Decisions for Investors

• Delay outright QQQM adds until early/mid-June weakness; if Nasdaq-100 draws down 3-5%, use it to initiate a 6-8 week tactical long with a 2:1 upside/downside profile.
• Overweight XLP versus QQQM on a 1-2 month horizon as a relative-value hedge against crowded AI exposure; target a modest 3-4% spread capture with tight stop if tech breadth re-accelerates.
• Build a long VHT / short QQQM pair for summer: healthcare offers lower AI correlation and better drawdown resistance; aim for 150-250 bps of relative outperformance over 6-10 weeks.
• For more aggressive positioning, sell June QQQM calls against a core long if you already own the benchmark; the near-term calendar risk is better monetized than outright adding beta into a seasonally soft month.
• Use any post-earnings rally in mega-cap tech to reduce concentration and rotate a portion into XLP/VHT, where the risk/reward is better if market leadership broadens beyond AI.